Ken Griffin Dia Medica Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.8 - $4.49 $19,320 - $30,981	6,900 Added 530.77%	8,200 $34,000
Q2 2024 Aug 14, 2024	SELL	$2.16 - $3.66 $9,936 - $16,836	-4,600 Reduced 77.97%	1,300 $3,000
Q1 2024 May 15, 2024	BUY	$2.58 - $3.23 $10,578 - $13,243	4,100 Added 227.78%	5,900 $16,000
Q4 2023 Feb 14, 2024	BUY	$2.05 - $2.99 $3,484 - $5,083	1,700 Added 1700.0%	1,800 $5,000
Q3 2023 Nov 14, 2023	SELL	$2.56 - $4.4 $17,664 - $30,360	-6,900 Reduced 98.57%	100 $0
Q2 2023 Aug 14, 2023	BUY	$1.53 - $4.4 $9,027 - $25,960	5,900 Added 536.36%	7,000 $30,000
Q1 2023 May 15, 2023	SELL	$1.32 - $1.89 $660 - $945	-500 Reduced 31.25%	1,100 $1,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $1.62 $1,807 - $2,592	1,600 New	1,600 $2,000

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $118M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.